DYN - NASDAQ

Dyne Therapeutics, Inc.

DYN·NASDAQ

$17.99

-3.4%

HealthcareBiotechnology

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.97B

EPS-3.4700

P/E Ratio-5.18

Earnings Date07/27/2026

dyn

Selling, General and Administrative Expenses

Last Annual Value

69.85M

3-Year CAGR

35%

5-Year CAGR

41%

10-Year CAGR

-6%

Adjust for Inflation

Dyne Therapeutics, Inc. Competitors Analysis of Selling, General and Administrative Expenses

DYN · NASDAQ

Company	Selling, General and Administrative Expenses	CAGR 3Y	CAGR 5Y	CAGR 10Y
Dyne Therapeutics, Inc. NASDAQ:DYN	69.85M	30.5%	19.5%	-8.0%
CG Oncology, Inc. Common stock NASDAQ:CGON	73.53M	95.1%	73.8%	N/A
Celcuity Inc. NASDAQ:CELC	27.20M	69.0%	59.9%	59.0%
Mirum Pharmaceuticals, Inc. NASDAQ:MIRM	257.03M	20.8%	34.1%	N/A
Apogee Therapeutics, Inc. NASDAQ:APGE	70.88M	42.3%	N/A	N/A
Ultragenyx Pharmaceutical Inc. NASDAQ:RARE	349.00M	4.1%	9.7%	18.3%
Soleno Therapeutics, Inc. NASDAQ:SLNO	132.13M	114.0%	65.0%	31.8%

Dyne Therapeutics, Inc. Fair Value Envelope

DYN · NASDAQ

Our analysis suggests that DYN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $17.99, this represents a potential HIDDEN relative to our calculated worth for Dyne Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $17.99

Related Guides

Blog Categories

Continue your DYN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.